YM BioSciences Completes Acquisition of DELEX

YM BioSciences, the cancer product development company, recently announced it has completed the purchase of DELEX Therapeutics (Mississauga, Canada), a private clinical stage biotechnology company developing inhalation delivered fentanyl products to treat cancer pain. DELEX's lead product is AeroLEF, a proprietary technology for the treatment of acute and breakthrough pain that has completed preliminary efficacy trials and will undergo further Phase II efficacy trials in 2005.

PR NewsWire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/05-03-2005/0003537573&EDATE=)